Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 immunogenicity and safety study of BIBP yellow fever vaccine in Kenyan infants, children, and adolescents
PACTR202101846812148Phase 3Not yet recruiting
- Sponsor
- Beijing Institute of Biological Products
- Start
- Jan 2021
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of 17D yellow fever vaccine and Measles and Rubella Vaccine (PT Bio Farma), sponsored by Beijing Institute of Biological Products. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
17D yellow fever vaccineMeasles and Rubella Vaccine (PT Bio Farma)
Beyond the preview
Go deeper on PACTR202101846812148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202101846812148.